A new cost analysis taking into account spending on ancillary health services suggests that prior cost analyses underestimated the anticipated costs of aducanumab.
Cannabis use was linked to significantly increased risk of delayed cerebral hemorrhage in patients with aneurysmal SAH, potentially due to vasospasm, new research suggests.
When considering the choice of oral anticoagulant in patients with atrial fibrillation, apixaban appears to be preferable to rivaroxaban, another new study suggests.